by Ethan Perlstein | Dec 6, 2017 | Perlara science |
This is the fourth post in an open science blog series about PERL101 (P101), a small molecule with big hopes. Demystifying drug discovery The default setting of biotech startups and pharma giants alike is stealth mode. At Perlara the default is set to open. As the...
by Ethan Perlstein | Nov 4, 2017 | Start-ups, Uncategorized |
This week we announced a $7.4M equity financing. Endpoints News and STAT News covered the announcement and the Twitter angle. Here’s the backstory from the CEO’s vantage point. From the outside, this round appears to be our Series A. But it’s technically our...
by Ethan Perlstein | Sep 21, 2017 | Niemann-Pick Type A |
By Taryn Sumabat This summer at Perlara, we ramped up our efforts to develop a Drosophila model of Niemann-Pick Type A (NPA). NPA is a rare lysosomal storage disease caused by mutations in the gene Smpd1, which encodes an enzyme called acid sphingomyelinase (ASM)....
by Ethan Perlstein | Jul 31, 2017 | Start-ups |
Perlara midsummer 2017 updates—We took a temporary hiatus from blogging starting in March right after my Rare Disease Day post. The reason: fundraising. Raising money is personally all-consuming for the CEO, as I’ll attest in an upcoming post. It’s also a...
by Ethan Perlstein | Mar 8, 2017 | Perlara science |
This post is dedicated to World Rare Disease Day (WRDD) 2017. It was at the WRRD four years earlier when the value proposition for Perlara crystalized in my mind. I went to NIH that frosty last day of February in order to meet with patient advocates and ask them one...
